MADRIGAL PHARMACEUTICALS, INC. annual report, FY2012

Business context and reporting period

This is Synta Pharmaceuticals Corp.’s Form 10-K for the fiscal year ended December 31, 2012, filed March 14, 2013. The request identifies Madrigal Pharmaceuticals, Inc., but the supplied filing is for Synta Pharmaceuticals Corp. (NASDAQ: SNTA), not Madrigal; confirm the intended issuer before relying on this summary.

Synta is a clinical-stage biopharmaceutical company developing small-molecule drugs, principally for cancer and inflammatory diseases. It had no product sales and retained ownership of its drug candidates. Its lead program was ganetespib, with additional clinical-stage work on elesclomol and preclinical programs.

Financial results and liquidity

Revenue in 2012 was grant revenue only; collaboration revenue was zero following termination of the Roche agreement. The operating loss increased as R&D spending rose, chiefly for ganetespib. Operating and net margins are not meaningful indicators given negligible revenue and the company’s development-stage business.

Year-end term-loan carrying value was approximately $12.388 million ($7.924 million current and $4.464 million long-term). Total liabilities were $27.951 million. GECC debt carried 9.75% interest and Oxford debt 13.35%; scheduled payments and related obligations were significant. Working capital and cash resources increased substantially after equity financings, not from operating cash generation.

Material changes versus prior comparable period

• Revenue fell 98% to $0.147 million from $7.584 million, reflecting the end of collaboration revenue and lower grant revenue.
• R&D expense rose 19% to $49.412 million. Ganetespib program costs increased 50%, to $45.1 million; elesclomol and CRACM spending declined.
• Net loss widened to $62.790 million from $47.380 million, while operating cash use increased to $54.135 million from $47.300 million.
• Cash, cash equivalents and marketable securities increased by $60.9 million, principally due to approximately $119.7 million of net equity proceeds during 2012. Shares outstanding increased from 49.5 million at year-end 2011 to 68.9 million at year-end 2012.
• Roche’s termination of the CRACM collaboration became effective in February 2012; rights to the relevant compounds reverted to Synta, with a low-single-digit royalty potentially payable on future sales.

Outlook, risks and unusual items

• Management estimated that existing cash resources would fund operations into the second quarter of 2014, assuming planned 2013 activities and available resources. It warned that additional funding could be needed sooner and that financing might not be available on acceptable terms.
• Management expected ganetespib R&D costs to increase in 2013 as trials advanced; it expected elesclomol costs to remain near 2012 levels, CRACM costs potentially to decline, and G&A to remain similar absent expanded pre-commercial activity.
• GALAXY-1 interim results in 172 adenocarcinoma patients showed median overall survival had not been reached in the ganetespib-plus-docetaxel arm versus 7.4 months with docetaxel alone. PFS was 4.2 versus 2.8 months (p=0.076), and response rates were 16% versus 8% (p=0.078). These interim results were not conclusive; the filing reported a 90% confidence interval for the overall-survival hazard ratio that included 1.0 in the full database analysis.
• Synta reported completing the initial GALAXY-1 enrollment target and advancing GALAXY-2, a planned 500-patient Phase 3 study. GALAXY-1 follow-up analyses were expected during 2013; GALAXY-2 interim and final overall-survival analyses were projected for 2014. These were forward-looking estimates, not reported outcomes.
• The ovarian-cancer elesclomol Phase 2 trial met its prespecified criterion to advance to stage 2. However, the filing notes prior negative or inconclusive elesclomol trials, including failure of the pivotal melanoma study to meet its primary endpoint.
• Key risks include clinical-trial failure or delay, regulatory uncertainty, no commercial products or sales infrastructure, reliance on third-party manufacturers and CROs, single-source manufacturing exposure, competition, patent challenges, and potential dilution or loss of rights if new capital or partnerships are required.
• The GECC loan is secured by substantially all assets other than intellectual property, with a potential springing IP security interest under specified covenant conditions. Debt agreements include restrictive covenants and default provisions.
• The filing reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure and internal controls. The auditor issued an unqualified opinion on the financial statements and internal control over financial reporting.

Important facts for investors to verify

1. Confirm the issuer mismatch: this filing is Synta Pharmaceuticals Corp., not Madrigal Pharmaceuticals, Inc.
2. Review the full audited statements and notes, including cash runway assumptions, debt covenants, scheduled loan payments and research-contract commitments.
3. Track subsequent GALAXY-1 and GALAXY-2 results against the interim data and planned timelines; assess statistical significance, patient selection and safety.
4. Assess how much additional financing would be needed, the potential dilution from equity issuance, and whether partnership discussions produced funding or cost sharing.
5. Verify the status of manufacturing scale-up, backup suppliers, and regulatory requirements for ganetespib and the elesclomol sodium formulation.